Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
A-HYDROCORT vs BRICANYL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrocortisone is a corticosteroid hormone that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation, inhibit immune response, and regulate metabolism.
Beta-2 adrenergic receptor agonist; stimulates adenyl cyclase, increasing cyclic AMP, leading to bronchodilation.
Adrenocortical insufficiency (primary and secondary),Congenital adrenal hyperplasia,Inflammatory conditions (e.g., rheumatoid arthritis, ulcerative colitis),Allergic reactions (severe),Asthma exacerbations,Dermatologic disorders (topical use),Ophthalmic inflammation (ophthalmic use)
Treatment or prevention of bronchospasm in patients with reversible obstructive airway disease,Acute asthma exacerbation,Off-label: Management of acute hyperkalemia,Off-label: Prevention of preterm labor (terbutaline)
Adrenal insufficiency: oral 20-30 mg/day in divided doses; inflammatory conditions: 5-60 mg/day oral; IV/IM: hydrocortisone sodium succinate 50-100 mg every 4-6 hours.
Subcutaneous: 0.25-0.5 mg every 1-2 hours as needed; Intravenous: 0.25-0.5 mg over 1 minute, may repeat every 1-2 hours; Inhalation (metered-dose inhaler): 2 inhalations (0.4 mg) every 6 hours; Nebulized: 2.5-5 mg every 6-8 hours.
Terminal half-life: 1.5-2 hours (cortisol); clinical effect persists 8-12 hours due to glucocorticoid receptor binding
3-4 hours (terminal); prolonged in renal impairment (up to 8-10 hours) and in elderly patients.
Primarily hepatic via CYP3A4 and other CYP450 enzymes, with reduction in the A-ring to inactive metabolites (e.g., tetrahydrocortisol).
Metabolized in the liver via sulfonation (sulfotransferase enzymes) and to a minor extent by catechol-O-methyltransferase (COMT).
Renal (primarily as metabolites, <1% unchanged); biliary/fecal (<5%)
Primarily renal (60-70% as unchanged drug and metabolites); fecal elimination accounts for a minor fraction (<5%).
90-95% bound to corticosteroid-binding globulin (CBG) and albumin
Approximately 25% bound to albumin.
0.5-0.8 L/kg; represents distribution into total body water, higher in obesity
~0.6 L/kg; indicates distribution into total body water.
Oral: 96% (well absorbed); IM/IV: 100%; topical: minimal systemic absorption (<1% with intact skin)
Inhalation: ~10-20% (dependent on device and technique); Oral: ~15-20% (due to extensive first-pass metabolism).
No specific adjustment required; monitor fluid/electrolytes in severe renal impairment.
No specific dose adjustment recommended for renal impairment; use with caution in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to potential for increased systemic exposure.
Dose reduction may be necessary in severe hepatic impairment; caution as metabolism is hepatic.
No specific dose adjustment recommended; caution in severe hepatic impairment (Child-Pugh Class C) due to reduced clearance.
Doses are weight-based; for adrenal insufficiency: 0.5-0.75 mg/kg/day in divided doses; for anti-inflammatory: 0.5-10 mg/kg/day.
Subcutaneous: 5-10 mcg/kg every 1-2 hours as needed (max 0.5 mg); Intravenous: 5-10 mcg/kg over 1 minute (max 0.5 mg); Inhalation (MDI): 1-2 inhalations (0.2-0.4 mg) every 4-6 hours; Nebulized: 0.01-0.03 mg/kg (max 1 mg) every 6-8 hours.
Use lowest effective dose; monitor for osteoporosis, hypertension, and glucose intolerance.
Initiate at lower end of dosing range (e.g., subcutaneous 0.125 mg); monitor for tachycardia, hypertension, and tremor; consider age-related decline in renal and hepatic function.
None.
Not available
Immunosuppression and increased infection risk,Adrenal suppression with prolonged use,Cushing's syndrome with chronic use,Osteoporosis with long-term use,GI perforation risk in inflammatory bowel disease,Growth suppression in children,Fetal harm (category C),Ocular effects (cataracts, glaucoma),Fluid and electrolyte disturbances
Paradoxical bronchospasm may occur,Cardiovascular effects (e.g., tachycardia, arrhythmias, increased blood pressure) use caution with cardiovascular disorders,Hypokalemia may occur,Hyperglycemia reported,Immediate hypersensitivity reactions
Systemic fungal infections,Hypersensitivity to hydrocortisone or any component,Administration of live or live-attenuated vaccines (relative),Herpes simplex keratitis (topical ophthalmic use),Peptic ulcer disease (relative),Uncontrolled hypertension (relative)
Hypersensitivity to any component,Tachydysrhythmias,Cardiac glycoside toxicity with arrhythmias
No specific food interactions. However, high-sodium foods may exacerbate fluid retention; a low-sodium diet is recommended if edema occurs. Grapefruit juice does not significantly affect hydrocortisone. Avoid alcohol due to additive gastric irritation.
No significant food interactions. However, avoid excessive caffeine intake (coffee, tea, cola) as it may exacerbate beta-agonist side effects like palpitations and tremor.
Hydrocortisone is a corticosteroid. Use during first trimester is associated with increased risk of oral clefts (odds ratio 1.5-3.0). Second and third trimester use may cause fetal adrenal suppression, growth restriction, and premature birth. Risk of premature rupture of membranes and intrauterine growth restriction increases with prolonged use.
Insufficient human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Risk cannot be excluded; use only if clearly needed. First trimester: limited data suggest no major malformations. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and transient hypocalcemia. Avoid in preterm labor due to maternal and fetal adverse effects.
Hydrocortisone is excreted into breast milk in low concentrations. M/P ratio approximately 0.4-1.0. Doses up to 20 mg/day are considered compatible with breastfeeding. Higher doses may suppress infant adrenal function; monitor infant for growth and adrenal suppression.
Excreted into breast milk in small amounts; M/P ratio approximately 2.5. No adverse effects reported in infants at therapeutic maternal doses. However, monitor infant for signs of beta-2 adrenergic stimulation (e.g., tachycardia, irritability). Consider risk-benefit.
Due to increased clearance and protein binding changes, doses may need to be increased by 50-100% in the second and third trimesters. Monitor clinical response and adjust dose accordingly. Stress doses (e.g., 50-100 mg IV) should be given during labor and delivery.
No specific dose adjustments recommended for asthma or COPD. However, in preterm labor (off-label), use lowest effective dose and shortest duration due to increased risk of maternal pulmonary edema, cardiac ischemia, and fetal effects. Monitor closely.
For acute adrenal insufficiency, give IV bolus of 100 mg hydrocortisone followed by 100 mg every 8 hours. Taper to oral replacement over days. In septic shock, stress-dose hydrocortisone (200 mg/day) may be used if vasopressor-dependent. Monitor for hyperglycemia, hypokalemia, and immunosuppression. Abrupt discontinuation can cause adrenal crisis.
BRICANYL (terbutaline sulfate) is a beta-2 adrenergic agonist used for bronchodilation in asthma and COPD. It can cause transient hypokalemia, hyperglycemia, and tremor. Use with caution in patients with diabetes, hypertension, or hyperthyroidism. Monitor serum potassium in patients on diuretics or with hypoxia. Not recommended for acute severe asthma as monotherapy; prefer short-acting beta-agonists like albuterol.
Take exactly as prescribed; do not stop suddenly without doctor's guidance.,Carry a medical alert card or bracelet indicating you take hydrocortisone.,Report signs of adrenal crisis: severe weakness, dizziness, nausea, vomiting, abdominal pain.,During illness or stress (e.g., surgery, infection), dose may need temporary increase; contact your doctor.,Avoid live vaccines during therapy.,Monitor for weight gain, swelling, mood changes, or high blood sugar symptoms (increased thirst, urination).
Use exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Shake the inhaler well before each use.,Rinse mouth with water after inhalation to prevent oral thrush.,Seek emergency medical help if breathing problems worsen or if you have chest pain or irregular heartbeat.,Monitor blood sugar if diabetic as this medication may raise blood glucose levels.,Avoid caffeine as it may increase side effects like nervousness and rapid heart rate.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about A-HYDROCORT vs BRICANYL, answered by our medical review team.
A-HYDROCORT is a Corticosteroid that works by Hydrocortisone is a corticosteroid hormone that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation, inhibit immune response, and regulate metabolism.. BRICANYL is a Beta-2 Agonist that works by Beta-2 adrenergic receptor agonist; stimulates adenyl cyclase, increasing cyclic AMP, leading to bronchodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between A-HYDROCORT and BRICANYL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of A-HYDROCORT is: Adrenal insufficiency: oral 20-30 mg/day in divided doses; inflammatory conditions: 5-60 mg/day oral; IV/IM: hydrocortisone sodium succinate 50-100 mg every 4-6 hours.. The standard adult dose of BRICANYL is: Subcutaneous: 0.25-0.5 mg every 1-2 hours as needed; Intravenous: 0.25-0.5 mg over 1 minute, may repeat every 1-2 hours; Inhalation (metered-dose inhaler): 2 inhalations (0.4 mg) every 6 hours; Nebulized: 2.5-5 mg every 6-8 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between A-HYDROCORT and BRICANYL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. A-HYDROCORT is classified as Category C. Hydrocortisone is a corticosteroid. Use during first trimester is associated with increased risk of oral clefts (odds ratio 1.5-3.0). Second and third trimester use may cause fetal. BRICANYL is classified as Category C. Insufficient human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Risk cannot be excluded; use only if clearly needed. First trimester: limit. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.